Section Arrow
Quote
LPCN.NASDAQ
- Lipocine
Quotes are at least 15-min delayed:2026/04/02 02:14 EDT
Regular Hours
Last
 9.25
+1.26 (+15.77%)
Day High 
9.2999 
Prev. Close
7.99 
1-M High
9.9095 
Volume 
171.30K 
Bid
7.4
Ask
9.6
Day Low
7.6 
Open
7.94 
1-M Low
6.89 
Market Cap 
44.36M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.4 
20-SMA 7.7 
50-SMA 8.65 
52-W High 12.37 
52-W Low 2.52 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.77/-1.35
Enterprise Value
46.62M
Balance Sheet
Book Value Per Share
1.98
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.98M
Operating Revenue Per Share
0.01
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics6.38+4.83+311.61%-- 
ELABPmgc Holdings Inc14+8.01+133.72%0PE
IOBTIO Biotech0.0437-0.015-25.55%-- 
APLSApellis Pharmaceuticals40.39+0.16+0.40%224.11PE
GERNGeron Corp1.66+0.17+11.41%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has otherproducts in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.